{"id":20317,"date":"2025-11-09T21:01:54","date_gmt":"2025-11-09T15:31:54","guid":{"rendered":"http:\/\/43.205.138.160\/?post_type=article&#038;p=20317"},"modified":"2025-11-09T21:01:54","modified_gmt":"2025-11-09T15:31:54","slug":"morepen-labs-%e0%a4%a8%e0%a4%b5%e0%a4%be%e0%a4%9a%e0%a4%be%e0%a4%b0-%e0%a4%b5%e0%a4%bf%e0%a4%b8%e0%a5%8d%e0%a4%a4%e0%a4%be%e0%a4%b0-%e0%a4%94%e0%a4%b0-%e0%a4%b8%e0%a5%87%e0%a4%b9%e0%a4%a4%e0%a4%ae","status":"publish","type":"article","link":"https:\/\/signalz.pro\/article\/morepen-labs-%e0%a4%a8%e0%a4%b5%e0%a4%be%e0%a4%9a%e0%a4%be%e0%a4%b0-%e0%a4%b5%e0%a4%bf%e0%a4%b8%e0%a5%8d%e0%a4%a4%e0%a4%be%e0%a4%b0-%e0%a4%94%e0%a4%b0-%e0%a4%b8%e0%a5%87%e0%a4%b9%e0%a4%a4%e0%a4%ae\/","title":{"rendered":"Morepen Labs: \u0928\u0935\u093e\u091a\u093e\u0930, \u0935\u093f\u0938\u094d\u0924\u093e\u0930, \u0914\u0930 \u0938\u0947\u0939\u0924\u092e\u0902\u0926 \u092d\u0935\u093f\u0937\u094d\u092f \u0915\u0940 \u0913\u0930 \u0926\u0943\u0922\u093c \u0915\u0926\u092e\ufeff"},"content":{"rendered":"<h2 class=\"mb-2 mt-4 font-display font-semimedium text-base first:mt-0\">Technical Analysis<\/h2>\n<ul class=\"marker:text-quiet list-disc\">\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>Trend<\/strong>: The stock is in a clear bearish phase.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>Indicators<\/strong>:<\/p>\n<ul class=\"marker:text-quiet list-disc\">\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Moving averages (daily): All short-term and long-term MAs indicate a strong sell with at least 12 sell signals and none for buy.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>RSI (14):<\/strong>\u00a020.9, in deep oversold territory \u2014 may hint at a potential technical bounce, but weakness persists.\u200b<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>MACD &amp; Bollinger Bands:<\/strong>\u00a0Bearish momentum, below the mean on both week and month charts; moderate trend strength, underperformance versus the Sensex.\u200b<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>Price Zone<\/strong>: As of Nov 7, 2025, closing near \u20b947. Key support at \u20b945\u201346; resistance at \u20b949.50\u2013\u20b951.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>Outlook<\/strong>: Only risk-tolerant traders should consider accumulating near \u20b945\u201346 with a tight stop; otherwise, trend remains down until a clear reversal above \u20b951.\u200b<\/p>\n<\/li>\n<\/ul>\n<hr class=\"bg-subtle h-px border-0\" \/>\n<h2 class=\"mb-2 mt-4 font-display font-semimedium text-base first:mt-0\">Fundamental Analysis<\/h2>\n<ul class=\"marker:text-quiet list-disc\">\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>Q1\u2013Q2 FY26 Results<\/strong>:<\/p>\n<ul class=\"marker:text-quiet list-disc\">\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>Revenue:<\/strong>\u00a0Around \u20b9425 crore quarterly (7.4% YoY growth); TTM revenue ~\u20b91,782 crore, positive but slowing.\u200b<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>Net Profit:<\/strong>\u00a0Q4 FY25 saw a 29% YoY drop to \u20b920.3 crore due to margin pressures and input costs; yearly bottomline trend still positive but volatile.\u200b<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>Valuation<\/strong>:<\/p>\n<ul class=\"marker:text-quiet list-disc\">\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">P\/E ~28.3 (TTM), considered high for current earnings and sector comps.\u200b<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">ROCE: 12.8%; Book value per share: \u20b941.6; P\/B: 2.23 indicates moderate premium.\u200b<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>Business Mix<\/strong>:<\/p>\n<ul class=\"marker:text-quiet list-disc\">\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Pharma API and branded drugs, diagnostics, and medical devices \u2013 expansion in glucometers, growing global APIs, strong R&amp;D.\u200b<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Revenue in medical devices and exports rising, but U.S. exports flat; Europe\/Asia strong.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>Balance Sheet<\/strong>: Moderate debt, solid liquidity (current ratio 2.4+), but ROE low at 10.2%.\u200b<\/p>\n<\/li>\n<\/ul>\n<hr class=\"bg-subtle h-px border-0\" \/>\n<h2 class=\"mb-2 mt-4 font-display font-semimedium text-base first:mt-0\">Upcoming News\/Events &amp; Impact<\/h2>\n<ul class=\"marker:text-quiet list-disc\">\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>Board Meeting \u2013 14 Nov 2025<\/strong>: Likely to review H1 and Q2 FY26 earnings and consider new capex\/expansion news; potential for stock movement based on profit outlook.\u200b<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>R&amp;D pipeline:<\/strong>\u00a0New launches in anti-diabetic\/orthopedics. Any big US regulatory or export update could act as a near-term trigger.\u200b<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>Strategic Investments:<\/strong>\u00a0\u20b9200 crore QIP recently raised for expansion in APIs and devices, enhancing future growth prospects.\u200b<\/p>\n<\/li>\n<\/ul>\n<hr class=\"bg-subtle h-px border-0\" \/>\n<h2 class=\"mb-2 mt-4 font-display font-semimedium text-base first:mt-0\">Disclaimer &amp; Disclosure<\/h2>\n<ul class=\"marker:text-quiet list-disc\">\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">This analysis is for educational\/informational use only.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">It does not constitute an investment, buy\/sell, or financial recommendation.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Investors are advised to perform their own due diligence and consult SEBI-registered advisors before investing.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Price trends and fundamentals can change with new data; past performance is not indicative of future returns.<\/p>\n<\/li>\n<\/ul>\n<p><a href=\"http:\/\/43.205.138.160\/wp-content\/uploads\/2025\/11\/MOREPEN-LAB-REPORT-FROM-THE-HOUSE-OF-INVESTOGAINER.pdf\">MOREPEN LAB REPORT FROM THE HOUSE OF INVESTOGAINER<\/a><\/p>\n","protected":false},"template":"","article-category":[35],"article-tags":[787,386,400,130,163,112,133,116,129,162,168,127],"class_list":["post-20317","article","type-article","status-publish","hentry","article-category-learn","article-tags-nifty-banknifty","article-tags-optionstrading","article-tags-technicalanalysis","article-tags-expert-analysis","article-tags-financialeducation","article-tags-financialplanning","article-tags-investment-strategies","article-tags-signalzinvestmenttips","article-tags-stock-market-tips","article-tags-stockmarket","article-tags-stockmarkettips","article-tags-successful-investing"],"acf":[],"_links":{"self":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article\/20317","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article"}],"about":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/types\/article"}],"wp:attachment":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/media?parent=20317"}],"wp:term":[{"taxonomy":"article-category","embeddable":true,"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article-category?post=20317"},{"taxonomy":"article-tags","embeddable":true,"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article-tags?post=20317"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}